Impact of APOE in mild cognitive impairment

Martin Farlow, Y. He, S. Tekin, J. Xu, R. Lane, H. C. Charles

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Objective: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition. Methods: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI. Results: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40% of the subjects were APOE ε4 carriers. APOE ε4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE ε4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups. Conclusion: MCI subjects carrying the APOE ε4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE ε4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.

Original languageEnglish
Pages (from-to)1898-1901
Number of pages4
JournalNeurology
Volume63
Issue number10
StatePublished - Nov 23 2004

Fingerprint

Activities of Daily Living
Genotype
Equipment and Supplies
Executive Function
Atrophy
Alleles
Prospective Studies
Depression
Cognitive Dysfunction

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Farlow, M., He, Y., Tekin, S., Xu, J., Lane, R., & Charles, H. C. (2004). Impact of APOE in mild cognitive impairment. Neurology, 63(10), 1898-1901.

Impact of APOE in mild cognitive impairment. / Farlow, Martin; He, Y.; Tekin, S.; Xu, J.; Lane, R.; Charles, H. C.

In: Neurology, Vol. 63, No. 10, 23.11.2004, p. 1898-1901.

Research output: Contribution to journalArticle

Farlow, M, He, Y, Tekin, S, Xu, J, Lane, R & Charles, HC 2004, 'Impact of APOE in mild cognitive impairment', Neurology, vol. 63, no. 10, pp. 1898-1901.
Farlow M, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004 Nov 23;63(10):1898-1901.
Farlow, Martin ; He, Y. ; Tekin, S. ; Xu, J. ; Lane, R. ; Charles, H. C. / Impact of APOE in mild cognitive impairment. In: Neurology. 2004 ; Vol. 63, No. 10. pp. 1898-1901.
@article{2f98cb4fd2384cc08751ba7db1a69919,
title = "Impact of APOE in mild cognitive impairment",
abstract = "Objective: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition. Methods: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI. Results: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40{\%} of the subjects were APOE ε4 carriers. APOE ε4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE ε4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups. Conclusion: MCI subjects carrying the APOE ε4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE ε4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.",
author = "Martin Farlow and Y. He and S. Tekin and J. Xu and R. Lane and Charles, {H. C.}",
year = "2004",
month = "11",
day = "23",
language = "English",
volume = "63",
pages = "1898--1901",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Impact of APOE in mild cognitive impairment

AU - Farlow, Martin

AU - He, Y.

AU - Tekin, S.

AU - Xu, J.

AU - Lane, R.

AU - Charles, H. C.

PY - 2004/11/23

Y1 - 2004/11/23

N2 - Objective: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition. Methods: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI. Results: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40% of the subjects were APOE ε4 carriers. APOE ε4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE ε4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups. Conclusion: MCI subjects carrying the APOE ε4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE ε4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.

AB - Objective: The authors aimed to use baseline data of an ongoing large, prospective study in subjects with mild cognitive impairment (MCI) to investigate the impact of APOE genotype on the symptom profile of the condition. Methods: Cognitive assessments included the AD Assessment Scale cognitive subscale (ADAS-cog), the Mini-Mental State Examination (MMSE), and a cognitive battery for assessment of memory, attention, and executive function. Behavioral assessments included the Neuropsychiatric Inventory and Beck Depression Inventory. Activities of daily living were assessed by the AD Cooperative Study Activities of Daily Living (ADCS-ADL) scale. Hippocampal volumes were measured with MRI. Results: A total of 494 of 1,018 study subjects provided APOE data. Approximately 40% of the subjects were APOE ε4 carriers. APOE ε4 carriers had lower MMSE (p = 0.01) and higher ADAS-cog (p < 0.0001) scores than noncarriers, indicating worse cognitive impairment. APOE ε4 carriers also had greater deficits on New York University delayed paragraph recall and Buschke free and cued selective reminding tests, and on the ADCS-ADL scale (p < 0.001). They also had smaller hippocampal volumes (p = 0.002). Behavioral scores were similar across the subgroups. Conclusion: MCI subjects carrying the APOE ε4 allele showed distinct cognitive and imaging profiles, which appeared to resemble those of early Alzheimer patients. APOE ε4 genotype was associated with greater impairments in memory and functional activities as well as hippocampal atrophy.

UR - http://www.scopus.com/inward/record.url?scp=8844273984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844273984&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 1898

EP - 1901

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -